WO2001087335A3 - Method for selectively inhibiting ghrelin action - Google Patents

Method for selectively inhibiting ghrelin action Download PDF

Info

Publication number
WO2001087335A3
WO2001087335A3 PCT/US2001/011752 US0111752W WO0187335A3 WO 2001087335 A3 WO2001087335 A3 WO 2001087335A3 US 0111752 W US0111752 W US 0111752W WO 0187335 A3 WO0187335 A3 WO 0187335A3
Authority
WO
WIPO (PCT)
Prior art keywords
selectively inhibiting
ghrelin
comprises administering
inhibiting ghrelin
ghrelin action
Prior art date
Application number
PCT/US2001/011752
Other languages
French (fr)
Other versions
WO2001087335A2 (en
Inventor
Henry Uhlman Bryant
Mark Louis Heiman
Original Assignee
Lilly Co Eli
Henry Uhlman Bryant
Mark Louis Heiman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Henry Uhlman Bryant, Mark Louis Heiman filed Critical Lilly Co Eli
Priority to AU2001259056A priority Critical patent/AU2001259056A1/en
Priority to US10/258,259 priority patent/US20030211967A1/en
Priority to EP01932539A priority patent/EP1286697A2/en
Publication of WO2001087335A2 publication Critical patent/WO2001087335A2/en
Publication of WO2001087335A3 publication Critical patent/WO2001087335A3/en
Priority to US11/106,899 priority patent/US20050201938A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hormone secretagogue receptor) antagonist.
PCT/US2001/011752 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action WO2001087335A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001259056A AU2001259056A1 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action
US10/258,259 US20030211967A1 (en) 2001-05-07 2001-05-07 Method for selectively inhibiting ghrelin action
EP01932539A EP1286697A2 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action
US11/106,899 US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20489700P 2000-05-17 2000-05-17
US60/204,897 2000-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/106,899 Continuation US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Publications (2)

Publication Number Publication Date
WO2001087335A2 WO2001087335A2 (en) 2001-11-22
WO2001087335A3 true WO2001087335A3 (en) 2002-05-16

Family

ID=22759933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011752 WO2001087335A2 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action

Country Status (3)

Country Link
EP (1) EP1286697A2 (en)
AU (1) AU2001259056A1 (en)
WO (1) WO2001087335A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906618B2 (en) 2000-02-18 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9266108B2 (en) 2004-03-12 2016-02-23 Life Technologies Corporation Nanoliter array loading
US9428800B2 (en) 2002-12-20 2016-08-30 Life Technologies Corporation Thermal cycling apparatus and method

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296809A1 (en) 2000-10-10 2002-04-22 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
JP4493913B2 (en) * 2001-01-31 2010-06-30 中外製薬株式会社 Undernutrition Symptom Treatment Agent
AU2002254800B2 (en) * 2001-05-10 2006-09-28 Queensland University Of Technology Reproductive cancer diagnosis and therapy
BR0212985A (en) 2001-09-24 2005-08-30 Imp College Innovations Ltd Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
ES2383796T3 (en) 2001-12-18 2012-06-26 Alizé Pharma SAS Pharmaceutical compositions comprising non-acylated ghrelin for use in the treatment of insulin resistance
WO2003097083A1 (en) * 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Medicinal compositions containing ghrelin
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ATE481133T1 (en) * 2002-07-05 2010-10-15 Chugai Pharmaceutical Co Ltd AGENTS FOR LOWERING BLOOD GLUCOSE LEVELS
ATE513041T1 (en) 2002-08-01 2011-07-15 Noxxon Pharma Ag GHRELIN BINDING NUCLEIC ACIDS
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2004056869A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
WO2005026211A2 (en) * 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CA2543507C (en) * 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
US7282050B2 (en) 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US7252665B2 (en) 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US20070031840A1 (en) * 2003-11-10 2007-02-08 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
EP1746983A2 (en) * 2004-05-14 2007-01-31 Novo Nordisk A/S Use of ghrelin antagonists for improving cognition and memory
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
JP2008515771A (en) * 2004-07-14 2008-05-15 イーライ リリー アンド カンパニー Anti-ghrelin antibody
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
EP1856154A1 (en) * 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
UY29460A1 (en) 2005-04-08 2006-11-30 Noxxon Pharma Ag NUCLEIC ACIDS FROM UNION TO GHRELIN
US7736392B2 (en) 2005-04-28 2010-06-15 Medtronic, Inc. Bulking of upper esophageal sphincter for treatment of obesity
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JP4879988B2 (en) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007092023A1 (en) 2006-02-11 2007-08-16 Boston Biomedical Research Institute Compositions and methods for binding or inactivating ghrelin
US20110143992A1 (en) * 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP5485876B2 (en) 2007-05-31 2014-05-07 アリゼ ファーマ エスアーエス Unacylated ghrelin as a therapeutic agent in the treatment of metabolic diseases
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
NZ592544A (en) 2008-10-30 2013-01-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JP2013509434A (en) 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
ES2705499T3 (en) 2011-12-15 2019-03-25 Millendo Therapeutics Sas Fragments of non-acylated ghrelin for use in the treatment of Prader-Willi syndrome
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
CN104994848A (en) 2013-02-22 2015-10-21 默沙东公司 Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3065757A4 (en) 2013-10-09 2017-08-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
MX2017002610A (en) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE.
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) * 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) * 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJIMA MASAYASU ET AL: "Ghrelin is a growth-hormone-releasing acylated peptide from stomach.", NATURE (LONDON), vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 656 - 660, XP002187791, ISSN: 0028-0836 *
SMITH R G ET AL: "A nonpeptidyl growth hormone secretagogue.", SCIENCE, (1993 JUN 11) 260 (5114) 1640-3., XP002187790 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906618B2 (en) 2000-02-18 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9518299B2 (en) 2000-02-18 2016-12-13 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9428800B2 (en) 2002-12-20 2016-08-30 Life Technologies Corporation Thermal cycling apparatus and method
US9266108B2 (en) 2004-03-12 2016-02-23 Life Technologies Corporation Nanoliter array loading

Also Published As

Publication number Publication date
EP1286697A2 (en) 2003-03-05
WO2001087335A2 (en) 2001-11-22
AU2001259056A1 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
WO2001087335A3 (en) Method for selectively inhibiting ghrelin action
MXPA01009544A (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids.
EP1427377A4 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
HUP0303976A3 (en) Combination therapy using anti-egfr antibodies and hormone antagonists
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
IL206829A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
WO2004103288A3 (en) Method of preventing recurrent miscarriages
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
ZA200201819B (en) Preventive and therapeutic agents for eye diseases.
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
YU20104A (en) Methods of treating pulmonary disease
MXPA01008993A (en) Combination treatment for depression and anxiety.
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
MXPA05013104A (en) Method for the treatment or prevention of lower urinary tract symptoms.
TW200617176A (en) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10258259

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001932539

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001932539

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP